Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | HPGDS | O60760 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 6/20 | 0.31 |
| ▸ | DRD2 | P14416 | 5/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687304 | 0.87 | PDE10A (0.34) | PDE10AHPGDSDRD3DRD2HTR2A | |
| SCHEMBL1847387 | 0.86 | PDE10A (0.40) | PDE10AHPGDSDRD3DRD2HTR2A | |
| SCHEMBL4686983 | 0.86 | PDE10A (0.41) | PDE10AHPGDSDRD3DRD2HTR2A | |
| SCHEMBL4686652 | 0.85 | PDE10A (0.38) | PDE10AHPGDSDRD2L3MBTL1 | |
| SCHEMBL4686584 | 0.85 | PDE10A (0.34) | PDE10AHPGDSDRD3DRD2HTR2A | |
| SCHEMBL4690219 | 0.85 | PDE10A (0.35) | PDE10AHPGDS | |
| SCHEMBL4691747 | 0.85 | PDE10A (0.37) | PDE10AHPGDSDRD3DRD2HTR2A | |
| SCHEMBL4691347 | 0.84 | TSHR (0.39) | PDE10AHPGDSDRD3DRD2HTR2A | |
| SCHEMBL4690301 | 0.83 | TSHR (0.38) | PDE10AHPGDSDRD3DRD2HTR2A | |
| SCHEMBL4693216 | 0.83 | PDE10A (0.35) | PDE10AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1443046-B1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | KYORIN SEIYAKU KK (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1443046-A1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | CYP4F2, CYP1A2, CYP4B1 | PDE10A 317/4885HPGDS 243/4885DRD3 894/4885 |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | OPRM1, OPRD1, HRH4 | PDE10A 2390/4885HPGDS 317/4885DRD3 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.